drugset / Trial / NCT00343161

Symptom Adapted Therapy in GERD Patients

NCT00343161

Phase 4 Completed 441 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether a maintenance treatment over 12 weeks with esomeprazole 20 mg daily will sufficiently give control over GERD symptoms and how it compares either with an on-demand therapy with esomeprazole 20 mg or an as needed therapy (wait and see regimen) with rescue medication only (antacid), following a 4-weeks acute treatment phase with either esomeprazole 20 mg or esomeprazole 40 mg.

Timeline

Start
2006-08
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg
Subject Esomeprazole Small molecule 40 mg
Background Aluminum hydroxide gel Unknown
Background TRISILICATE Small molecule